

Pietro A Canetta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7722079/publications.pdf>

Version: 2024-02-01

60
papers

4,369
citations

218592

26
h-index

168321

53
g-index

61
all docs

61
docs citations

61
times ranked

5395
citing authors

#	ARTICLE	IF	CITATIONS
1	Sensitivity and Specificity of a Single Emergency Department Measurement of Urinary Neutrophil Gelatinase-Associated Lipocalin for Diagnosing Acute Kidney Injury. <i>Annals of Internal Medicine</i> , 2008, 148, 810.	2.0	597
2	Diagnostic Utility of Exome Sequencing for Kidney Disease. <i>New England Journal of Medicine</i> , 2019, 380, 142-151.	13.9	456
3	Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. <i>New England Journal of Medicine</i> , 2019, 381, 36-46.	13.9	324
4	Diagnostic and Prognostic Stratification in the Emergency Department Using Urinary Biomarkers of Nephron Damage. <i>Journal of the American College of Cardiology</i> , 2012, 59, 246-255.	1.2	306
5	Kidney Biopsy Findings in Patients with COVID-19. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1959-1968.	3.0	301
6	Ecuzimab for Dense Deposit Disease and C3 Glomerulonephritis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 748-756.	2.2	295
7	Acute Kidney Injury Due to Collapsing Glomerulopathy Following COVID-19 Infection. <i>Kidney International Reports</i> , 2020, 5, 940-945.	0.4	182
8	A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1306-1313.	3.0	174
9	Whole-Exome Sequencing in Adults With Chronic Kidney Disease. <i>Annals of Internal Medicine</i> , 2018, 168, 100.	2.0	154
10	C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy. <i>Kidney International</i> , 2018, 93, 977-985.	2.6	123
11	The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis. <i>Nature Communications</i> , 2020, 11, 1600.	5.8	120
12	Systematic Review and Meta-Analysis of Native Kidney Biopsy Complications. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1595-1602.	2.2	103
13	Rationale and design of the Kidney Precision Medicine Project. <i>Kidney International</i> , 2021, 99, 498-510.	2.6	94
14	Treatment of Idiopathic FSGS with Adrenocorticotrophic Hormone Gel. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 2072-2081.	2.2	86
15	Interstitial fibrosis scored on whole-slide digital imaging of kidney biopsies is a predictor of outcome in proteinuric glomerulopathies. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 310-318.	0.4	85
16	Treatment of Resistant Glomerular Diseases with Adrenocorticotrophic Hormone Gel: A Prospective Trial. <i>American Journal of Nephrology</i> , 2012, 36, 58-67.	1.4	83
17	CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease. <i>American Journal of Kidney Diseases</i> , 2019, 73, 218-229.	2.1	68
18	Mycophenolate Mofetil in Combination with Steroids for Treatment of C3 Glomerulopathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 406-413.	2.2	63

#	ARTICLE	IF	CITATIONS
19	A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR). <i>Nephron</i> , 2015, 130, 159-168.	0.9	49
20	Kidney Transplantation in C3 Glomerulopathy: A Case Series. <i>American Journal of Kidney Diseases</i> , 2019, 73, 316-323.	2.1	48
21	Rituximab treatment for fibrillary glomerulonephritis. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1925-1931.	0.4	47
22	Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study. <i>Kidney International Reports</i> , 2018, 3, 1373-1384.	0.4	39
23	Health-related quality of life in glomerular disease. <i>Kidney International</i> , 2019, 95, 1209-1224.	2.6	38
24	Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy. <i>Journal of the American Society of Hypertension</i> , 2012, 6, 338-345.	2.3	35
25	Predicting Post-Transplant Recurrence of IgA Nephropathy: The Importance of Crescents. <i>American Journal of Nephrology</i> , 2017, 45, 99-106.	1.4	35
26	Longitudinal Outcomes of COVID-19-Associated Collapsing Glomerulopathy and Other Podocytopathies. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2958-2969.	3.0	31
27	The clinicopathologic spectrum of segmental membranous glomerulopathy. <i>Kidney International</i> , 2021, 99, 247-255.	2.6	30
28	Glomerular Diseases. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 617-625.	2.2	28
29	Pilot Study of Return of Genetic Results to Patients in Adult Nephrology. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 651-664.	2.2	28
30	Nonalbumin proteinuria predominates in biopsy-proven tenofovir nephrotoxicity. <i>Aids</i> , 2015, 29, 941-946.	1.0	26
31	Impact of the ALMS and MAINTAIN trials on the management of lupus nephritis. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 1371-1376.	0.4	25
32	Lack of Serologic Evidence to Link IgA Nephropathy with Celiac Disease or Immune Reactivity to Gluten. <i>PLoS ONE</i> , 2014, 9, e94677.	1.1	25
33	Rationale and design of the Transformative Research in Diabetic Nephropathy (TRIDENT) Study. <i>Kidney International</i> , 2020, 97, 10-13.	2.6	23
34	How COVID-19 Has Changed the Management of Glomerular Diseases. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 876-879.	2.2	23
35	The Evidence-Based Approach to Adult-Onset Idiopathic Nephrotic Syndrome. <i>Frontiers in Pediatrics</i> , 2015, 3, 78.	0.9	21
36	Cadherin-11, Sparc-related modular calcium binding protein-2, and Pigment epithelium-derived factor are promising non-invasive biomarkers of kidney fibrosis. <i>Kidney International</i> , 2021, 100, 672-683.	2.6	21

#	ARTICLE	IF	CITATIONS
37	Does NGAL reduce costs? A cost analysis of urine NGAL (uNGAL) & serum creatinine (sCr) for acute kidney injury (AKI) diagnosis. PLoS ONE, 2017, 12, e0178091.	1.1	21
38	An Open-Label Pilot Study of Adrenocorticotrophic Hormone in the Treatment of IgA Nephropathy at High Risk of Progression. Kidney International Reports, 2020, 5, 58-65.	0.4	17
39	Longitudinal Changes in Health-Related Quality of Life in Primary Glomerular Disease: Results From the CureGN Study. Kidney International Reports, 2020, 5, 1679-1689.	0.4	17
40	Anti-neutrophil cytoplasmic antibody associated glomerulonephritis complicating treatment with hydralazine. Kidney International, 2021, 100, 440-446.	2.6	17
41	Concurrent Anti-Glomerular Basement Membrane Antibody Disease and Membranous Nephropathy: A Case Series. American Journal of Kidney Diseases, 2021, 78, 219-225.e1.	2.1	16
42	Use of Bortezomib in Heavy-Chain Deposition Disease: Report of 3 Cases. American Journal of Kidney Diseases, 2014, 64, 123-127.	2.1	15
43	Diagnostic Approach to Glomerulonephritis With Fibrillar IgG Deposits and Light Chain Restriction. Kidney International Reports, 2021, 6, 936-945.	0.4	14
44	A 56-year-old woman with sarcoidosis and acute renal failure. Kidney International, 2008, 74, 817-821.	2.6	13
45	Predictors of outcome for severe IgA Nephropathy in a multi-ethnic U.S. cohort. Clinical Nephrology, 2015, 84 (2015), 145-155.	0.4	13
46	Clinical Predictors and Prognosis of Recurrent IgA Nephropathy in the Kidney Allograft. Glomerular Diseases, 2022, 2, 42-53.	0.2	9
47	Glomerular Diseases in Patients with Diabetes Mellitus: An Underappreciated Epidemic. Kidney360, 2020, 1, 220-222.	0.9	9
48	Impact of the National Institutes of Health Focal Segmental Glomerulosclerosis (NIH FSGS) clinical trial on the treatment of steroid-resistant FSGS. Nephrology Dialysis Transplantation, 2013, 28, 527-534.	0.4	8
49	Patient perspectives and involvement in precision medicine research. Kidney International, 2021, 99, 511-514.	2.6	5
50	A Participant-Centered Approach to Understanding Risks and Benefits of Participation in Research Informed by the Kidney Precision Medicine Project. American Journal of Kidney Diseases, 2022, 80, 132-138.	2.1	3
51	Persistent Disease Activity in Patients With Long-Standing Glomerular Disease. Kidney International Reports, 2020, 5, 860-871.	0.4	2
52	Toward a Clearer Picture of IgA Nephropathy in Spondyloarthritis. Kidney International Reports, 2020, 5, 766-768.	0.4	1
53	New and emerging treatments for lupus nephritis. Dialysis and Transplantation, 2011, 40, 67-71.	0.2	0
54	Su1445 Lack of Serologic Evidence for an Association Between Gluten Sensitivity and IgA Nephropathy. Gastroenterology, 2014, 146, S-471.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Idiopathic Immune Complex Glomerulonephritis. , 2017, , 1-10.		0
56	A Case of Iatrogenic Dehydration. American Journal of Kidney Diseases, 2019, 74, A15-A18.	2.1	0
57	Ask and It Shall Be Given. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 594-596.	2.2	0
58	Late Relapses of Membranous Nephropathy: A Case Series. Kidney360, 2021, 2, 974-982.	0.9	0
59	Mixed Cryoglobulinemia. , 2017, , 1-13.		0
60	Disentangling a Case of Glomerulonephritis with Fibrils. Clinical Journal of the American Society of Nephrology: CJASN, 0, , CJN.00630122.	2.2	0